The non-antiemetic uses of serotonin 5-HT3 receptor antagonists - Clinical pharmacology and therapeutic applications

Drugs

Volumn 53, Issue 1, 1997, Pages 20-39

  Greenshaw, Andrew J ^a   Silverstone, Peter H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPROPYLMETHOXY N (8 METHYL 8 AZABICYCLO[3.2.1]OCTAN 3 YLCARBAMOYL)BENZAMIDE; 4 AMINO 1 (6 CHLORO 2 PYRIDYL)PIPERIDINE; ALOSETRON; ANTIDEPRESSANT AGENT; CHOLECYSTOKININ; DOPAMINE; FLUOXETINE; GRANISETRON; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; ONDANSETRON; PHENELZINE; RENZAPRIDE; RICASETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TROPISETRON; ZACOPRIDE;

ALCOHOLISM; ANTIEMETIC ACTIVITY; ANXIETY NEUROSIS; APPETITE DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG USE; HUMAN; IRRITABLE COLON; NONHUMAN; PAIN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TASTE AVERSION;

ANIMALIA;

EID: 0031027610     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753010-00003     Document Type: Review

References (188)

1. Moulignier A. Central serotonin receptors: principal fundamental and functional aspects. Therapeutic applications. Rev Neurol Paris 1994; 150: 3-15
2. 3 mediated control of dopaminergic function. Psychopharmacology 1993; 112: S60-7
3. Elliott JM, Flanigan TP, Newberry NR, et al. 5-HT receptor subtypes: aspects of their regulation and function. Neurochem Int 1994; 25: 537-43
4. 3 antagonists. Therapie 1991; 46: 431-5
5. Launay JM, Callebert J, Bondoux D, et al. Serotonin receptors and therapeutics. Cell Mol Biol 1994; 40: 327-36
6. 3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology 1993; 112: S68-75
7. Marty M, Pouillart P, Schol S, et al. Comparison of the 5-hydroxytryptamine-3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816-21
8. 3 receptors: pharmacologic and therapeutic aspects. J Clin Pharmacol 1995; 35: 845-55
9. 3 receptors in rat brain using radioligand binding. Nature 1987; 330: 746-8
10. 3 receptors are membrane ion channels. Nature 1989; 339: 706-8
11. 3 receptor channel. Annu Rev Physiol 1995; 57: 447-68
12. 3 receptors. J Neurochem 1995; 65: 104-10
13. 3 receptor-A mRNA in NG108-15 cells. J Neurochem 1995; 65: 1917-25
14. 3 receptor, a serotonin gated ion channel. Science 1991; 254: 432-7
15. Miyake A, Mochizuki S, Takemoto Y, et al. Molecular cloning of human 5-hydroxytryptamine-3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol 1995; 48: 407-16
16. Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacology 1994; 33: 275-317
17. 3 receptor agonist. Eur J Pharmacol 1990; 182: 193-7
18. 3 receptors in vitro and in vivo. Eur J Pharmacol 1993; 237: 299-309
19. 4 receptor. Med Res Rev 1993; 13: 633-62
20. 3 receptor antagonists: a critical update on therapeutic potential. Trends Pharmacol Sci 1993; 14: 265-70
21. 3 antagonists. Psychopharmacology 1990; 100: 459-63
22. 3 receptor antagonist ICS 205-930 on place aversion conditioning. Eur J Pharmacol 1988; 151: 321-4
23. 3 receptors. Psychopharmacology 1989; 97: 489-95
24. 3 receptor antagonists do not block nicotine induced hyperactivity in rats. Psychopharmacology 1995; 119: 213-21
25. 3 receptors. Pharmacol Toxicol 1992; 71: 401-15
26. Griebel G. 5-Hydroxytryptamine-interacing drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 1995; 65: 319-95
27. 3-receptor antagonists. Psychopharmacology 1991; 104: 545-51
28. Rezazadeh SM, Prather PL, Emmett-Oglesby MW, et al. Evaluation of anxiolytic action of ondansetron in rats during withdrawal from chronic chlordiazepoxide. Ann NY Acad Sci 1992; 264: 472-3
29. 3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat. Psychopharmacology 1989; 99: 248-51
30. 3 receptor antagonists, GR38032F and BRL 24924, on anxiety in socially isolated rats [abstract]. Br J Pharmacol 1989; 97: 457P
31. Andrews N, File SE. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur J Pharmacol 1993; 235: 109-12
32. 3 receptor antagonist, BRL-46470A, on the behaviour of mice in a 2 compartment light dark box and during social interactions in their home cage and unfamiliar neutral cage. Neuropharmacology 1992; 31: 743-8
33. 3 receptor antagonist, in two animal models of anxiety. Eur J Pharmacol 1992; 218: 327-33
34. 3 receptor antagonist with anxiolytic-like properties. Psychopharmacology 1993; 110: 257-64
35. 3 binding sites compared to 3H-granisetron. Br J Pharmacol 1995; 116: 1781-8
36. Nevins ME, Anthony EW. Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity? J Pharmacol Exp Ther 1994; 268: 248-68
37. Olivier B, Molewijk E, van Oorschot R, et al. New animal models of anxiety. Eur Neuropsychopharmacol 1994; 4: 93-102
38. A and 5-HT anxiolytics. Psychopharmacology 1995; 121: 38-56
39. 3 antagonists: a review. Stress Med 1992; 8: 117-36
40. 3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats. Eur J Pharmacol 1990; 185: 179-86
41. 3 receptor stimulation. Pharmacol Biochem Behav 1993; 45: 755-7
42. 3 antagonist ondansetron on benzodiazepine-induced operant behavioural dependence in rats. Psychopharmacology 1992; 109: 461-5
43. 3 receptor activation in the rat increases adrenocortical secretion at the level of the central nervous system. Neurosci Res Commun 1994; 14: 167-73
44. 3 antagonist BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers. Biol Psychiatry 1994; 36: 309-16
45. 3 receptors in rat cerebral cortex and nucleus accumbens. Br J Pharmacol 1991; 103: 1790-4
46. Harro J, Vasar E, Bradwejn J. Cholecystokinin in animal and human research on anxiety. Trends Pharmacol Sci 1993; 14: 244-9
47. Lecrubier V, Puech AJ, Azcona A, et al. A randomised double-blind placebo-controlled study of tropisetron in the treatment of outpatients wilh generalized anxiety disorder. Psychopharmacology 1993; 112: 129-33
48. Mosconi M, Chiamulera C, Recchia G. New anxiolytics in development. Int J Clin Pharm Res 1993; 13: 331-44
49. 3 receptor antagonist GR38032F on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain Br J Pharmacol 1987; 92: 881-94
50. 3 receptors in the central nervous system [abstract]. Br J Pharmacol 1987; 90: 89P
51. 3 antagonists. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven. 1992: 211-23
52. 3 receptor antagonist. GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain. Eur J Pharmacol 1987; 138: 303-5
53. 3 receptor in the pressure-induced increase in striatal and accumbens dopamine release and the occurrence of behavioral disorders in free-moving rals. Neurosci Lett 1995; 197: 57-60
54. Layer RT, Uretsky NJ, Wallace LJ. Effect of serotonergic agonists in the nucleus accumbens on d- amphetamine-stimulated locomotion. Life Sci 1992; 50: 813-20
55. 3 receptor agonist induced carrier-mediated release of dopamine in rat striatum in vivo. Br J Pharmacol 1995; 116: 1545-50
56. 3 receptor antagonists block morphine- and nicotine- but not amphetamine-induced reward. Psychopharmacology 1989; 97: 175-8
57. 3 receptor antagonists. MDL 72222 and ondansetron on morphine place conditioning. Psychopharmacology 1992; 106: 315-20
58. 3 receptors control dopamine release in nucleus accumbens of freely moving rats. Neurosci Lett 1989; 101: 214-7
59. 3 receptor antagonists on the morphine-induced excitation of A10 dopamine cells: electrophysiological studies. Brain Res 1994; 638: 325-8
60. 3 receptor antagonist, fails to alter the number of spontaneously active midbrain dopamine neurons. Eur J Pharmacol 1990; 175: 347-50
61. 3 antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons. Eur J Pharmacol 1991; 205: 113-6
62. 3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 1989; 163: 115-8
63. 3 antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur J Pharmacol 1993; 230: 63-8
64. 3 receptor antagonists on the discriminative stimulus effects of amphetamine. Eur J Pharmacol 1990; 212: 271-4
65. Volonté M, Ceci A, Borsini F. Effect of the 5-hydroxytryplamine3 receptor antagonist itasetron (DAU 6214) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an in vivo microdialysis study. J Pharmacol Exp Ther 1995; 275: 358-67
66. Geissler MA, Torrente JR, Eison AS, et al. Effects of BMY 33462, a selective and potent serotonin type-3 receptor antagonist, on mesolimhic dopamine-mediated behavior. Drug DevRes 1993; 29: 18-24
67. Greenshaw AJ. Differential effects of ondansetron, haloperidol and clozapine on electrical self-stimulation of the ventral tegmental area. Behav Pharmacol 1993; 4: 479-85
68. 3 antagonists ondansetron, zacopride, 3-tropanyl-1H-indole-3-carboxylic acid ester, and 1H, 3, 5H-tropan-3-yl-3,5-dichlorobenzoate. Drug Dev Res 1991; 23: 289-300
69. 3 receptor antagonist ondansetron on hypothalamic self-stimulation in rats and its interaction with the CCK analogue caerulein. Neurosci Lett 1992; 140: 16-8
70. Ivanova S, Allison K, Greenshaw AJ. Effects of ondansetron on the rewarding and aversive stimulus properties of nicotine. Proceedings of the 16th Annual Meeting of the Canadian College of Neuropsychopharmacology; 1993
71. Lane JD, Pickering CL, Hooper ML, et al. Failure of ondansetron to block the discriminative or reinforcing stimulus properties of cocaine in the rat. Drug Alcohol Depend 1992; 30: 151-62
72. 3 receptor antagonist, ondansetron, on brain stimulation reward, and its interaction with direct and indirect stimulants of central dopaminergic transmission. J Neural Transm 1993; 91: 1-11
73. 3 antagonist ondansetron on electrical self-stimulation of the VTA in rats [abstract]. Clin Neuropsychopharmacol 1992: 15 (B): P88
74. 3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding. Psychopharmacology 1990; 101: 168-71
75. 3 receptor antagonists on neuroleptic-induced catalepsy in mice. Neuropharmacology 1995; 34: 97-9
76. McMillen BA, Scott SM, Davanzo EA. Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J Pharm Pharmacol 1988; 40: 885-7
77. White A, Corn T, Feetham C, et al. Ondansetron in treatment of schizophrenia. Lancet 1991; 337: 1173
78. Breier A. Serotonin, schizophrenia and antipsycholic drug action. Schizophr Res 1995; 14: 187-202
79. Newcomer JW, Faustman WO, Zipursky RB, et al. Zacopride in schizophrenia; a single-blind serotonin type 3 antagonist trial. Arch den Psychiat 1992; 49: 751-2
80. Meltzer HY. Studies on ondansetron in schizophrenia. Biol Psychiatry 1991; 2: 891-3
81. 3 receptor antagonist. Neurology 1995; 45: 1305-8
82. 3 receptors in schizophrenia: a postmortem study of the amygdala. Brain Res 1993; 616: 53-7
83. 3 receptor recognition sites in the putamen ol patients with Huntington's disease. Eur J Pharmacol 1993; 242: 137-43
84. 3 receptor antagonist, blocks MDMA's ability to establish a conditioned place-preference. Pharmacol Biochem Behav 1991; 39: 509-12
85. 3 receptor antagonists attenuate cocaine-induced locomotion m mice. Eur J Pharmacol 1990; 186: 327-30
86. 3 antagonists ICS 205-930 and MDL 72222. Pharmacol Biochem Behav 1994; 49: 67-71
87. 3 antagonists do not alter the discriminative stimulus properties of cocaine Psychopharmacol 1991; 104: 475-8
88. 3 antagonist, fails to alter cocaine self administration in rats. Pharmacol Biochem Behav 1991; 39: 133-6
89. Lacosta S, Roberts DCS. MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine. Pharmacol Biochem Behav 1993; 45: 161-5
90. Depoortere RY, Li DH, Lane JD, et al. Parameters of self-administration of cocaine in rats under a progressive-ratio schedule. Pharmacol Biochem Behav 1993; 45: 1-10
91. 3 agonist-induced dopamine overflow during withdrawal front continuous or intermittent cocaine administration. Psychopharmacology 1995; 117: 458-65
92. 3r eceptor antagonist, partially attenuates the effects of amphetamine: a pilot study in volunteers. Int Clin Psychopharmacol 1992; 7: 37-43
93. 3 antagonist ondansetron (O) for cocaine (C)-likc activity and abuse potential [abstract]. NIDA Res Monogr 1991; 105S: 515
94. 4 receptors on place preference conditioning. Pol J Pharmacol 1993; 45: 513-9
95. 3 antagonists re duce morphine sell-administration in rats. Br J Pharmacol 1993; 110: 1341-6
96. 3 receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats. Psychopharmacology 1994; 114: 611-9
97. 3 receptor antagonists on the discriminative stimulus properties of morphine in rats. Psychopharmacology 1993; 112: 111-5
98. Sell LA, Cowen PJ, Robson PJ. Ondansetron and opiate craving: a novel pharmacological approach to addiction. Br J Psychiatry 1995; 166: 511-4
99. Zacny JP, Apfelbaum JL, Lichtor JL, et al. Effects of 5-hydroxytryptamine3 antagonist, ondansetron, on cigarette smoking, smoke exposure and mood in humans. Pharmacol Biochem Behav 1993; 44: 387-91
100. Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. Trends Pharmacol Sci 1992; 13: 69-75
101. 3 receptors in drug dependence. Drug Alcohol Depend 1995; 38: 155-71
102. Cooper SJ, Barber DJ. Effects of d-fenfluramine, MK-212, and ondansetron on saline drinking in two-choice tests in the rehydrating rat. Pharmacol Biochem Behav 1993; 45: 593-6
103. Jankowska E, Ridzinski A, Kostowski W. Alcohol drinking in rats treated with 5,7-dihydroxytryptamine: effect of 8-OH-DPAT and tropisetron (ICS 205-930). Alcohol 1994; 11: 283-8
104. 3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18: 879-85
105. 3 receptor interactions in animals and humans. Drug Dev Res 1993; 30: 153-69
106. Doty P, Zacny JP, de Wit H. Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. Behav Pharmacol 1994; 5: 461-9
107. 3 antagonist MDL-72222 exacerbates ethanol withdrawal seizures in mice. Alcoholism: Clin Exp Res 1994; 18: 410-4
108. 3 receptor antagonist ICS 205-930 to inhibit alcohol preference and withdrawal seizures in rats. Alcohol 1993; 10: 369-73
109. 3 antagonists fail to affect ethanol self-administration of rats. Alcohol 1994; 11: 389-95
110. 3 antagonists on normal and morphine-attenuated sexual behaviours in female and male rats. Experientia 1993; 49: 238-41
111. 3 on reproductive behaviors in rats. Psychopharmacology 1994; 115: 245-8
112. Shepherd JK, Rodgers RJ. 8-OH-DPAT specifically enhances feeding behaviour in mice: evidence from behavioural competition. Psychopharmacology 1990; 101: 408-13
113. Hammer VA, Gietzen DW, Beverly JL et al. Serotonin 3 receptor antagonists block anorectic responses to amino acid imbalance. Am J Physiol 1990; 259: R627-36
114. Jiang JC, Gietzen DW. Aromatic response to amino acid imbalance: a selective serotonin-3 effect. Pharmacol Biochem Behav 1994; 47: 59-63
115. 3 antagonists block aversion to saccharin in an amino acid-imbalanced diet. Am J Physiol 1995; 268: R1203-8
116. Fleicher PJ, Davies M. Effects of 8-OH-DPAT, buspirone and ICS 205-930 on feeding in a novel environment: comparison with chlordiazepoxide and FG-7142. Psychopharmacology 1990; 102: 301-8
117. Higgins GA, Tomkins DM, Fleicher PJ, et al. Effect of drugs influencing 5-HT function on ethanol drinking and feeding behavior in rats: studies using a drinkometer system. Neurosci Biobehav Rev 1992; 16: 535-52
118. Beczkowska IW, Bodnar RJ. Naloxone and serotonin receptor subtype antagonists; interactive effects upon deprivation-induced intake. Pharmacol Biochem Behav 1991; 38: 605-10
119. 3 receptor antagonist ondansetron augments the anorectic effects of d-amphetamine in non-deprived rats. Pharmacol Biochem Behav 1993; 45: 589-92
120. 3 antagonist reduces palatable food consumption in the non-deprived rat. Neuropharmacology 1994; 33: 805-11
121. 3 receptor antagonists. Expert Opin Ther Patents 1996; 6: 471-81
122. 3 recognition sites in membranes of cal and rabbit vagus nerve and superior cervical ganglion. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 396-402
123. 4 receptors. Br J Pharmacol 1995; 114: 1017-25
124. 3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal corlex. Psychopharmacology 1995; 119: 15-9
125. Blier P, Bouchard C. Functional characterisation of a 5-HT(3)-receptor which modulates the release of 5-HT in the guinea pig brain. Br J Pharmacol 1993; 108: 13-22
126. 3 receptors in rat nodose ganglion neurones. Br J Pharmacol 1994; 112: 741-4
127. 3 receptor-mediate current by the selective serolonin uptake inhibitor, fluoxetine. Neurosci Lett 1994; 173: 210-2
128. 3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology 1994; 33: 501-7
129. 3H]noradrenaline in rat brain limbic structures. Eur J Pharmacol 1994; 256: 269-79
130. 3 receptor agonist, in rodents. J Neural Trans 1995; 102: 83-90
131. 3 receptor antagonist and antiemetic properties. Eur J Pharmacol 1993; 232: 139-45
132. Boyer WF, Feighner JP. An overview of fluoxetine, a new serotonin-specific antidepressant. Mount Sinai J Med 1989; 56: 136-40
133. Feighner JP, Boyer WF, Meredith CH, et al. A placebo controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression [abstract]. Int Clin Psychopharmacol 1989; 4: 239
134. Laws D, Ashford JJ, Anstee JA. A multicenter double-blind comparative trial of fluvoxamine versus lorazepum in mixed anxiety and depression treated in general practice [abstract]. Acta Psychiatr Scand 1990; 81: 185
135. 3 receptor ligands in the regulation of sleep-wakefulness and raphe neuronal activity in the rat. Neuropharmacology 1992; 31: 519-29
136. 3 receptor antagonism by tropisetron on the sleep EEG and on nocturnal hormone secretion. Neuropsychopharmacology 1994; 11: 101-6
137. 3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature 1989; 338: 762-3
138. Domeney AM, Costall B, Gerrard PA, et al. The effect of ondansetron on cognitive performance in the marmoset. Pharmacol Biochem Behav 1991; 38: 169-75
139. 3 receptor ligands lack modulatory influence on acetylcholine release in rat entorhinal cortex. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 241-7
140. Maura G, Andrioli GC, Cavazzani P, et al. 5-Hydroxytryptamine-3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release. J Neurochem 1992; 58: 2334-7
141. 3 receptors. J Neurochem 1994; 62: 2254-61
142. Dawson GR, Heyes CM, Iversen SD. Pharmacological mechanisms and animal models of cognition. Behav Pharmacol 1992; 3: 285-97
143. 3) antagonist on electrophysiological properties of the rat hippocampus. Br J Pharmacol 1994; 112: 695-703
144. 3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task. Pharmacol Biochem Behav 1994; 47: 95-9
145. 3-receptor antagonist, selectivley antagonizes scopolamine-induced deficit in a passive-avoidance task, but not scopolamine-induced hypermotility in rats. J Pharm Pharmacol 1993; 45: 841-3
146. 3 receptor antagonist, WAY 100289, enhances spatial memory in rats with ibotenate lesions of the forebrain cholinergic projection system. Psychopharmacology 1995; 117: 318-32
147. Fontana DJ, Daniels SE, Henderson C, et al. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology 1995; 120: 409-17
148. 3 antagonist ICS 205-930. Pharmacol Toxicol 1991; 69: 105-6
149. 3 receptor antagonism on hippocampal theta thythm, memory and LTP induction in the freely moving rat. J Neurosci 1995; 15: 2445-52
150. Reikkmen Jr P, Sirvo J, Rekkinen P. Non-reversal of scopolamine- or age-related EEG changes by ondansetron, methylsergide or alaproclate. Psychopharmacology 1991; 103: 567-70
151. Jakala P, Sirvio J, Riekkinen PJ. The effects of tacrine and zacopride on the performance of adult rats in the working memory task. Gen Pharmacol 1994; 24: 675-9
152. Bratt AM, Kelly E, Domeney AM, et al. Ondansetron fails to attenuate a scopolamine-induced deficit in at Stone maze task. Neuroreport 1994; 5: 1921-4
153. 3 antagonists and disorders of cognition. In: Racagni G, Brunello N, Langer SZ, editors. Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. Int Acad Biomed Drug Res Basel, Karger, 1994; 7: 89-93
154. 3 receptor antagonist GR68755 on a scopolamine induced cognitive deficit in healthy subjects [abstract]. Br J Clin Pharmacol 1991; 32: 546P
155. Crook TH, Lakin M. Effects of ondansetron in age-associated memory impairment. Proceedings of 5th World Congress of Psychiatry; 1991: Florence
156. 3 receptor recognition sites in Alzheimer's disease. Neuroreport 1990; 1: 253-4
157. 3 receptors modulate spinal nociceptive reflexes. Brain Res 1990; 510: 12-6
158. Meiler ST, Lewis SJ, Brody MJ, et al. Vagal afferent-mediated inhihition of a nociceptive reflex by iv serotonin in the rat II role of the 5-HT receptor subtypes. Brain Res 1992; 585: 71-86
159. 3 receptor antagonists on the writhing response in mice. Gen Pharmac 1995; 26: 1301-6
160. 3H] LY278584. Brain Res 1991; 553: 149-54
161. 3 receptor binding sites are on capsaicin-sensitive fibres in ral spinal cord. Eur J Pharmacol 1989; 164: 315-22
162. 3 receptors in the rat spinal cord: immunohistochemistry and in situ hybridization. Neuroreport 1995; 6: 257-61
163. 3H] zacopride as radioligands. Synapse 1992; 10: 271-81
164. 3-mediated anti-nociception - possible release of GABA. J Neurosci 1991; 11: 1881-8
165. 3 receptor agonists following 5,7-dihydroxytryplamine. Eur J Pharmacol 1994; 264: 249-57
166. 3 receptors. Eur J Pharmacol 1993; 249: 151-60
167. 3 recognition sites in the rat gastrointestinal tract. Br J Pharmacol 1992; 106: 693-6
168. 4 receptors in ascending and descending re-flexes to the circular muscle of guinea-pig small intestine. Br J Pharmacol 1994; 112: 1095-100
169. 3-receptor antagonism: evidence for heterogeneous efficacy among different antagonists in guinea-pigs. J Pharm Pharmacol 1994; 46: 666-70
170. 3 receptor antagonists in modulation of visceral hypersensitivity. Br J Pharmacol 1995; 114: 558-62
171. 3 receptor antagonists in visceromotor and nociceptive responses to rectal distension before and during experimental colitis m rats. Fundam Clin Pharmacol 1994; 8: 553-62
172. 3 receptor antagonists: 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome. J Med Chem 1993; 36: 3286-92
173. 3 receptors in stress-induced colonic motor alterations in rats. Eur J Pharmacol 1993; 233: 193-9
174. 3 receptor antagonist, in patients with irritable bowel syndrome (IBS) [abstract]. Gut 1990; 31: A1174
175. 3 antagonist in irritable bowel syndrome (IBS) [abstract] Gastroenterol 1991; 100: A468
176. 3) antagonist ondansetron (GR38032F) in diarrhoea predominant irritable bowel syndrome (IBS) [abstract]. Gastroenterology 1990; 98: A394
177. Steadman CJ, Talley NJ, Phillips SF, et al. Selective 5-hydroxytryptamine type 3 receptor antagonism as treatment for diarrhoea-predominant irritable bowel syndrome - a pilot study. Mayo Clin Proc 1992; 67: 732-8
178. 3 antagonist (ondansetron) on rectal sensitivity and compliance in health and irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 543-51
179. Loisy C, Beorchia S, Centonze V, et al. Effects on migraine headache of MDL 72222, an antagonist at neuronal 5-HT receptors, double-blind, placebo-controlled study. Cephalalgia 1985; 5: 79-82
180. Couturier EGM, Hering R, Foster CA, et al. First clinical study of the
181. Rowal BMT, Merrill CF, Davis A, et al. A double-blind comparison of granisetron and placebo for the treatment of acute migraine in the emergency department. Cephalalgia 1991; 11: 207-13
182. 3 receptor antagonist in a multicenter trial fur acute migraine. Neuropharmacology 1994; 33: 509-13
183. 3 receptor antagonist, in the prevention of migraine attacks: a complex answer to a simple question. Pain 1991; 45: 283-92
184. Hughes JB. Metoclopramide in migraine treatment. Med J Aust 1977; 2: 580
185. Grauers O, Danneskiold-Samsoe P, Hasselgren KH, et al. Metoclopramide in acute pain caused by gallbladder- or kidney-stones [abstract]. Scand J Gastroenterol 1982; 17: A886
186. Rosenblatt WF, Cioffi AM, Sinatra R, et al. Metoclopramide: an adjunct to patient-controlled analgesia. Anesth Analg 1991; 73: 553-5
187. Coppola M, Yealy DM, Liebold RA. Randomized placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995; 26: 541-6
188. Kandler D, Lisander B. Analgesic action of metoclopramide in prosthetic hip surgery. Acta Anaesthesiol Scand 1993; 37: 49-53